PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price fell 0.1% during trading on Friday . The stock traded as low as $0.5310 and last traded at $0.5402. Approximately 57,214 shares were traded during trading, an increase of 548% from the average session volume of 8,831 shares. The stock had previously closed at $0.5405.
PharmaCyte Biotech Stock Down 0.1%
The business’s fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $0.69.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
